(Q37685668)

22 August 2017

1 reference

title

Heterodimerization of dopamine receptors: new insights into functional and therapeutic significance (English)

1 reference

protein heterodimerization activity

22 August 2017

0 references

1 reference

Roberto Maggio

1

1 reference

22 August 2017

Gabriella Aloisi

2

1 reference

22 August 2017

Elena Silvano

3

1 reference

22 August 2017

Mario Rossi

4

1 reference

22 August 2017

Mark J Millan

5

1 reference

22 August 2017

language of work or name

1 reference

1 December 2009

1 reference

Parkinsonism and Related Disorders

22 August 2017

published in

1 reference

22 August 2017

volume

15 Suppl 4

1 reference

22 August 2017

page(s)

S2-7

1 reference

G protein-coupled receptor oligomerization provides the framework for signal discrimination

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

Basic concepts in G-protein-coupled receptor homo- and heterodimerization.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

A monomeric G protein-coupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

The impact of G-protein-coupled receptor hetero-oligomerization on function and pharmacology

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

Allosteric modulation of heterodimeric G-protein-coupled receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

Adenosine A2A receptor and dopamine D3 receptor interactions: evidence of functional A2A/D3 heteromeric complexes

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

Dopamine D1 and D2 receptor Co-activation generates a novel phospholipase C-mediated calcium signal

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

D2/D3 dopamine receptor heterodimers exhibit unique functional properties

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

Partial agonist actions of aripiprazole and the candidate antipsychotics S33592, bifeprunox, N-desmethylclozapine and preclamol at dopamine D(2L) receptors are modified by co-transfection of D(3) receptors: potential role of heterodimer formation.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

Dopamine receptor signaling

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

Dopamine D3 receptors expressed by all mesencephalic dopamine neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

Dopamine autoreceptor regulation of release and uptake in mouse brain slices in the absence of D(3) receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

Coordinated Expression of Dopamine Receptors in Neostriatal Medium Spiny Neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

Pramipexole--a new dopamine agonist for the treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

Ropinirole: a review of its use in the management of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

Dopamine receptor agonists in the therapy of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

Human dopamine D(3) receptors mediate mitogen-activated protein kinase activation via a phosphatidylinositol 3-kinase and an atypical protein kinase C-dependent mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

Signaling mechanisms of the D3 dopamine receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

Mechanism of new antipsychotic medications: occupancy is not just antagonism

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

Antipsychotic drug action: antagonism, inverse agonism or partial agonism

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

Strategy for modulation of central dopamine transmission based on the partial agonist concept in schizophrenia therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

Crystal structure of rhodopsin: A G protein-coupled receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

Rhodopsin dimers in native disc membranes

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

The fourth transmembrane segment forms the interface of the dopamine D2 receptor homodimer.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

Crosstalk in G protein-coupled receptors: changes at the transmembrane homodimer interface determine activation

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

Cooperative conformational changes in a G-protein-coupled receptor dimer, the leukotriene B(4) receptor BLT1.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

Structure of the rhodopsin dimer: a working model for G-protein-coupled receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

Allosteric interactions between GB1 and GB2 subunits are required for optimal GABA(B) receptor function

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

G-protein-coupled receptor heterodimerization modulates receptor function

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

Evidence for adenosine/dopamine receptor interactions: indications for heteromerization

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

Sensitization of adenylate cyclase by Galpha i/o-coupled receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

Molecular mechanisms of excitatory signaling upon chronic opioid agonist treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

Pathological gambling caused by drugs used to treat Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

Antiparkinsonian medication and pathological gambling

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

Selective antagonism at dopamine D3 receptors as a target for drug addiction pharmacotherapy: a review of preclinical evidence

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970826-0

7 January 2021

10.1016/S1353-8020(09)70826-0

Identifiers

DOI

1 reference

22 August 2017

1 reference